GTX Corp/ US3624082059 /
2022-09-19 9:59:36 PM | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.0050USD | - | 205,954 Turnover: 873.1463 |
-Bid Size: - | -Ask Size: - | 0.0050 | 0.0035 |
GlobeNewswire
03-12
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
GlobeNewswire
03-12
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...
GlobeNewswire
03-04
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
GlobeNewswire
02-20
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
GlobeNewswire
02-15
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
02-15
Garrett Motion Delivers Strong 2023, Issues 2024 Outlook, Authorizes New $350M Share Repurchase Prog...
GlobeNewswire
02-12
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
02-09
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Particip...
GlobeNewswire
02-06
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm t...
GlobeNewswire
02-05
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treat...
GlobeNewswire
01-31
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire
01-30
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Ma...
GlobeNewswire
01-30
Garrett Motion to Hold Fourth Quarter and Full Year 2023 Financial Results Conference Call on Thursd...
GlobeNewswire
01-23
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
GlobeNewswire
01-08
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
01-07
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Upda...
GlobeNewswire
01-03
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire
01-03
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline